<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapies for acquired von Willebrand syndrome (aVWS)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapies for acquired von Willebrand syndrome (aVWS)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Therapies for acquired von Willebrand syndrome (aVWS)</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Therapy</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Therapies directed at treatment of bleeding (or prevention of surgical bleeding)</td> </tr> <tr> <td class="indent1">DDAVP (desmopressin)</td> <td> <ul> <li>Intravenous dose: 0.3 mcg/kg (maximum dose 20 mcg) in 50 mL saline over 20 min </li> </ul> </td> <td> <ul> <li>Can be repeated every 12 to 24 hours, but tachyphylaxis occurs after 3 to 5 doses. </li> <li>Follow response at 1 and 4 hours (assay VWF and factor VIII activities). </li> <li>Follow serum sodium after 2 to 3 doses to avoid hyponatremia (may need to discontinue). </li> <li>Use with caution in patients with cardiovascular disease. </li> </ul> </td> </tr> <tr> <td class="indent1">VWF concentrate (plasma-derived or recombinant)</td> <td> <ul> <li>Plasma-derived: Usual starting dose, 40 to 60 units/kg intravenously </li> <li>Recombinant: Usual starting dose, 80 units/kg intravenously </li> </ul> </td> <td> <ul> <li>Follow response (VWF and factor VIII activities) at 1 and 4 hours to estimate half-life. </li> <li>Adjust dose and frequency of infusion depending on clinical course. </li> <li>Consider continuous infusion if therapy is effective but half-life is short. </li> </ul> </td> </tr> <tr> <td class="indent1">Antifibrinolytic agents (tranexamic acid or epsilon aminocaproic acid)</td> <td> <ul> <li>TXA: 10 mg/kg intravenously 3 times per day <strong>or</strong> 25 mg/kg orally every 6 to 8 hours </li> <li>EACA: 25 to 50 mg/kg orally 4 times per day </li> </ul> </td> <td> <ul> <li>Either agent may be used. </li> <li>Generally given as adjunctive therapy with other treatments. </li> <li>Reduce dose in patients with kidney failure. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Recombinant activated factor VII (rFVIIa)</td> <td> <ul> <li>NovoSeven RT*: Usual dose, 90 mcg/kg intravenously every 4 to 6 hours </li> </ul> </td> <td> <ul> <li>Use for life-threatening bleeding after other therapies fail. </li> <li>Avoid in patients with cardiovascular risk. </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Therapies directed at increasing VWF levels and decreasing the levels of autoantibodies<sup>¶</sup></td> </tr> <tr> <td class="indent1">IVIG</td> <td> <ul> <li>1 gram/kg intravenously over several hours, once per day for 2 days (total dose, 2 grams/kg) </li> </ul> </td> <td> <ul> <li>Most effective in IgG MGUS and in other autoantibody-mediated disease. </li> <li>May take 2 to 3 days to prevent clearance of VWF and raise VWF activity levels in patients with a response. </li> </ul> </td> </tr> <tr> <td class="indent1">Plasmapheresis</td> <td> <ul> <li>One exchange every 2 to 3 days, with each exchange consisting of 1 to 1.5 plasma volumes </li> </ul> </td> <td> <ul> <li>May use as a temporizing measure (with other treatments) in patients with multiple myeloma or other disorders with high paraprotein levels. </li> <li>In most cases, a total of 3 to 5 procedures. </li> <li>Use albumin as replacement fluid. </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The underlying disorder responsible for aVWS should be treated whenever possible. Use specific treatments for bleeding. Medications can be combined in many cases. Other therapies with other mechanisms of action have been described in case reports; examples include rituximab (immunosuppressive), lenalidomide (anti-angiogenic), or octreotide (reduce portal blood flow). We generally do not use these therapies, as experience is very limited and they are not approved for aVWS. Refer to UpToDate for a more comprehensive discussion of the diagnosis and treatment of aVWS.</div><div class="graphic_footnotes">aVWS: acquired von Willebrand syndrome; VWF: von Willebrand factor; TXA: tranexamic acid; EACA: epsilon aminocaproic acid; rFVIIa: recombinant activated factor VII; IVIG: intravenous immune globulin; Ig: immunoglobulin; MGUS: monoclonal gammopathy of undetermined significance.<br/>* An alternative rFVIIa product, SevenFact, is available but not approved for aVWS. Dosing for NovoSeven RT and Sevenfact are not interchangeable; refer to the product information for details.<br/>¶ Therapies directed at lowering autoantibody levels and preventing immune destruction of VWF are only appropriate for individuals with immune-mediated aVWS.</div><div id="graphicVersion">Graphic 129086 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
